Rare Disease Drug Development
Location: South Korea
Investors 2
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| 31.07.2023 | Premier Pa... | premierpar... |
Mentions in press and media 17
| Date | Title | Description |
| 10.11.2025 | Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate" | 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual me... |
| 07.05.2025 | TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids | Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endome... |
| 20.03.2025 | TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development | Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) in China SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- ... |
| 05.10.2024 | The Next Frontier in Cancer Treatment: ABL Bio and TiumBio Forge Ahead with Innovative Therapies | In the relentless battle against cancer, two South Korean biopharmaceutical companies, ABL Bio and TiumBio, are making significant strides. Their recent announcements signal a promising future for patients grappling with advanced solid tumo... |
| 04.10.2024 | TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218 | TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) The first patient with head and neck squamous cell carcinoma was d... |
| 24.06.2024 | TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024 | TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-life in a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors TiumBio presented interim ... |
| 24.06.2024 | TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024 | TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-life in a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors TiumBio presented interim ... |
| 01.06.2024 | TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting | Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors A 40% overall response rate (ORR) and 100% disease control rate (DCR) w... |
| 01.06.2024 | TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting | Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors A 40% overall response rate (ORR) and 100% disease control rate (DCR) w... |
| 08.05.2024 | TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain | The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) Merigolix is expected to emerge as a best-i... |
Show more